NASDAQ$LFCR

Lifecore Biomedical Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Landec Corporation reported first quarter fiscal year 2023 results, with Lifecore segment revenues and EBITDA increasing.

Landec Corporation reported a 4.1% increase in consolidated revenues, driven by an 8.0% increase in Lifecore segment revenues. The company is progressing with its strategy to divest Curation Foods assets and focus on Lifecore CDMO business.

  • Consolidated revenues increased by 4.1% year-over-year to $43.4 million.
  • Lifecore segment revenues increased by 8.0% to $23.7 million year-over-year.
  • Consolidated net loss from continuing operations was $12.1 million, including $2.7 million of restructuring and non-recurring charges.
  • The company is reiterating its full year fiscal 2023 guidance for Lifecore and Corporate segments.

Headline financials

Total Revenue

$43.4M

Previous: $129M-66.3%
EPS (adj)

-$0.32

Previous: -$0.23-39.1%
Capital Expenditures

$3.36M

Previous: -$7.91M+142.5%
Free Cash Flow

-$4.46M

Previous: -$17.4M+74.3%
Net Income

-$12.1M

Previous: -$9.48M-27.3%
Operating Income

-$8.16M

Previous: -$3.81M-114.2%
Gross Profit

$5.82M

Previous: $17.5M-66.8%
Cash & Equivalents

$4.22M

Previous: $1.45M+191.8%
Total Assets

$266M

Previous: $446M-40.2%
Stock-Based Comp

$785K

Previous: $620K+26.6%

Revenue & EPS history

Lifecore Biomedical · Revenue · Quarterly

$43.4M

Q1 2023-66.3%vs Q1 2022
Beat estimate in 9 of 14 quarters(64%)
ActualEstimate

Revenue by segment

Lifecore Biomedical · $24.3M total across 1 segment · Q4 2023

  • CDMO Revenue
    $24.3M

Forward guidance

The Company is reiterating its full year fiscal 2023 guidance for its Lifecore and Corporate segments.

Tailwinds

  • Lifecore segment revenue: range of $122 million to $126 million (+12% to +15%)
  • Lifecore segment adjusted EBITDA: range of $31.0 million to $32.5 million (+7% to +12%)

Headwinds

  • Other segment (corporate expense): range of ($7.0) million to ($7.5) million
  • Consolidated adjusted EBITDA*: range of $23.5 million to $25.5 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

-2.1%

Avg return

Earnings day

-2.7%

Avg return

5 days after

-0.4%

Avg return

30 days after

40%

25 / 63 earnings

Positive

+19.5%

Q2 2013

Best reaction

-66.7%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026-3.9%-13.0%+8.9%
Q1 2026-0.1%+7.5%+12.5%
Q4 2025-6.3%-0.3%-3.0%
Q3 2025-22.3%-8.5%+7.0%
Q1 2025+8.1%-3.6%+24.8%
Q4 2024-21.0%-27.0%-21.0%
Q3 2024+8.2%+15.7%-5.0%
Q2 2024+8.2%+15.7%-5.0%
Q1 2024+8.2%+15.7%-5.0%
Q4 2023-13.2%-13.7%-16.8%
Q3 2023-0.5%+3.8%+18.1%
Q2 2023-66.7%-35.1%-23.6%
Q1 2023-5.3%-5.4%+4.0%
Q4 2022+4.7%+7.1%-6.0%
Q3 2022-8.3%-9.6%-20.8%
Q2 2022-1.8%-8.1%-2.5%
Q1 2022-9.6%-10.4%-4.7%
Q4 2021-6.8%-12.4%-10.5%
Q3 2021-10.4%-10.0%+12.0%
Q2 2021-2.2%-0.9%-0.8%
Q1 2021+1.2%+0.8%-2.7%
Q4 2020-14.4%-9.0%-9.4%
Q3 2020+15.3%+15.6%+31.6%
Q2 2020-11.3%-10.5%-1.0%
Q1 2020-3.6%-6.1%-9.4%
Q4 2019+5.2%-1.1%+3.7%
Q3 2019-9.3%-17.5%-18.7%
Q2 2019-12.4%-3.6%+8.1%
Q1 2019-0.2%-4.1%-2.5%
Q4 2018-5.7%-5.3%-5.3%
Q3 2018+6.5%+3.4%+1.9%
Q2 2018+3.2%+3.2%+4.8%
Q1 2018+11.3%+8.4%+9.6%
Q4 2017-7.7%-9.4%-8.7%
Q3 2017+10.1%+19.7%+16.0%
Q2 2017-2.5%-2.2%-10.9%
Q1 2017+5.6%+5.3%+4.4%
Q4 2016+2.1%+1.1%+10.9%
Q3 2016+0.5%
Q2 2016-0.1%
Q1 2016-4.0%
Q4 2015-1.3%
Q3 2015+1.2%
Q2 2015-1.5%
Q1 2015-2.0%
Q4 2014+5.0%
Q3 2014-2.7%
Q2 2014+1.1%
Q1 2014-8.4%
Q4 2013-2.7%
Q3 2013+4.0%
Q2 2013+19.5%
Q4 2010-1.7%
Q1 2013-0.3%
Q4 2012+0.9%
Q3 2011-0.5%
Q3 2012-0.5%
Q2 2011-0.5%
Q2 2012-0.5%
Q1 2011+1.5%
Q1 2012+1.5%
Q4 2011+1.5%
Q3 2010+5.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro